Michigan
PDAB

Back to PDAB Policy Center

Information, updates, and engagement opportunities related to the
Prescription Drug Affordability Board (PDAB).

Statute:

Pending before the Michigan Legislature, SB483

PDAB (includes public meeting notices):

Meeting notices:

Past meeting notices:

Public Comments

Letters and testimony submitted regarding state PDAB activity

CANN Public Comment: Michigan SB 3, SB 4, SB 5 — PDAB Legislation

Publication date:

4/22/25

Comment opposing Michigan's PDAB bills (SB 3, SB 4, SB 5), citing inadequate cost-benefit analysis, PBM pricing manipulation issues, and risks to safety-net programs without patient-centered reforms.

View PDF

CANN Letter: Michigan SB 483 Opposition

Publication date:

10/20/23

Letter opposing Michigan SB 483 establishing a PDAB, highlighting Colorado PDAB process failures and recommending patient-centered amendments for any future legislation.

View PDF

CANN Written Testimony: Michigan SB 483

Publication date:

9/19/23

Testimony opposing Michigan SB 483, recommending amendments to prioritize patient representation, define therapeutic alternatives, and protect 340B-dependent programs.

View PDF